Last updated: 23 February 2024 at 5:46pm EST

Jon L Giacomin Net Worth




The estimated Net Worth of Jon L Giacomin is at least $8.71 Million dollars as of 20 August 2018. Jon Giacomin owns over 2,890 units of Organogenesis stock worth over $185,989 and over the last 9 years Jon sold ORGO stock worth over $8,521,962.

Jon Giacomin ORGO stock SEC Form 4 insiders trading

Jon has made over 5 trades of the Organogenesis stock since 2016, according to the Form 4 filled with the SEC. Most recently Jon sold 2,890 units of ORGO stock worth $150,136 on 20 August 2018.

The largest trade Jon's ever made was selling 47,251 units of Organogenesis stock on 15 August 2016 worth over $3,910,965. On average, Jon trades about 5,848 units every 33 days since 2015. As of 20 August 2018 Jon still owns at least 72,652 units of Organogenesis stock.

You can see the complete history of Jon Giacomin stock trades at the bottom of the page.



What's Jon Giacomin's mailing address?

Jon's mailing address filed with the SEC is C/O ORGANOGENESIS HOLDINGS INC., 85 DAN ROAD, CANTON, MA, 02021.

Insiders trading at Organogenesis

Over the last 5 years, insiders at Organogenesis have traded over $157,938,506 worth of Organogenesis stock and bought 15,146,267 units worth $65,732,558 . The most active insiders traders include Capital Managing Member Iv,..., Alan A.Erani Albert Erani D..., and Glenn H Wisdom Starr Nussdorf. On average, Organogenesis executives and independent directors trade stock every 24 days with the average trade being worth of $1,067,103. The most recent stock trade was executed by Patrick Bilbo on 28 March 2024, trading 152,250 units of ORGO stock currently worth $179,655.



What does Organogenesis do?

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic allograft wound covering and surgical barrier for application in the care of chronic and acute wounds or surgical implantation in spine, orthopedic, and sports medicine applications; Apligraf, a bioengineered bi-layered skin substitute for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft, a dermal substitute for the treatment of DFUs; NuShield, a dehydrated placental tissue wound covering and surgical barrier applied to the target tissue to support native healing; and PuraPly Antimicrobial, an antimicrobial barrier skin substitute to treat chronic and acute wounds. Its surgical and sports medicine products comprise NuCel, a surgically implanted allograft used primarily in spinal and orthopedic surgical applications; ReNu, a cryopreserved suspension used to support healing of soft tissues; and FiberOS and OCMP used as a bone void filler primarily in orthopedic and neurosurgical applications. The company's pipeline products include PuraPly XT and PuraPly MZ to treat chronic, acute, and open wounds; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; Novachor, a chorionic membrane wound covering; TransCyte, a bioengineered tissue for the treatment of partial thickness burns; and Gintuit, a bioengineered bi-layered living cellular tissue for the treatment of mucogingival conditions in adults. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales force and independent agencies. The company was founded in 1985 and is headquartered in Canton, Massachusetts.



Complete history of Jon Giacomin stock trades at Cardinal Health and Organogenesis

Insider
Trans.
Transaction
Total value
Jon L Giacomin
CEO and Medical Segment
Sale $150,136
20 Aug 2018
Jon L Giacomin
CEO and Medical Segment
Sale $549,896
15 Feb 2018
Jon L Giacomin
CEO and Medical Segment
Option $968,032
12 May 2017
Jon L Giacomin
CEO and Medical Segment
Sale $3,910,965
15 Aug 2016
Jon L Giacomin
CEO and Medical Segment
Sale $3,910,965
15 Aug 2016


Organogenesis executives and stock owners

Organogenesis executives and other stock owners filed with the SEC include: